Regeneron Pharma (REGN) strong bull flag forming after a recent nice run above the 200-day moving average and out of a long basing pattern, a move above $593 an official trigger. REGN has seen some small contract but large net dollar value call buys for August and September with earnings scheduled for 8-5. The current flag measures to a $650 target. REGN’s Dupixent is turning into a blockbuster while investors appear overly concerned with Eylea competition slowing growth.